MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from issuance of
common stock, net
$3,585,308
Net cash provided by
financing activities
$3,585,308
Net change in cash
$1,570,019
Canceled cashflow
$2,015,289
Accrued interest,
related parties
-$18,637
Change in the fair value
of warrant...
$4,178
Depreciation
$518
Net cash used in
operating activities
-$2,015,289
Canceled cashflow
$23,333
Net loss
-$1,123,714
Prepaid and other
current assets
$707,953
Accounts payable and
accrued expenses
-$191,956
Due to related
parties
-$14,999
Back
Back
Cash Flow
source: myfinsight.com
Liminatus Pharma, Inc. (LIMNW)
Liminatus Pharma, Inc. (LIMNW)